Welcome to our dedicated page for Inovio Pharmaceu SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inovio Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biotechnology company developing DNA medicines for HPV-related diseases, cancer and infectious diseases. Form 8-K disclosures cover financial results, business updates, material agreements, at-the-market offering activity, warrant amendments and changes affecting security-holder rights.
Proxy materials describe shareholder voting matters, board governance, executive compensation and equity-award disclosures. The filing record also identifies the company’s registered common stock and capital-structure instruments, including common stock, Series A warrants and pre-funded warrants tied to public financing activity.
Inovio Pharmaceuticals, Inc. filed an amendment to its prospectus supplement for a previously registered offering of 14,285,715 shares of common stock together with Series A and Series B warrants, or related pre-funded warrants. The amendment updates the terms of the outstanding Series A Warrants by extending their expiration time to 5:00 p.m. New York City time on March 31, 2026, while leaving all other warrant terms unchanged.
The company’s common stock trades on the Nasdaq Capital Market under the symbol INO, and the closing sale price was $1.51 per share on January 26, 2026. The amendment is meant to be read together with the original prospectus and its prior supplements when evaluating an investment in these securities.
Inovio Pharmaceuticals, Inc. has amended its outstanding Series A warrants to extend their expiration. The warrants, originally set to expire on January 28, 2026, will now be exercisable until 5:00 p.m. New York City time on March 31, 2026. These Series A warrants were issued in Inovio’s July 2025 underwritten public offering and are exercisable for up to 13,564,268 shares of common stock, or pre-funded warrants in lieu of common stock. The exercise price is $1.75 per share of common stock, or $1.749 per pre-funded warrant. All other terms of the Series A warrants remain unchanged.
Inovio Pharmaceuticals entered an underwriting agreement for a public offering of 13,158,000 shares of common stock at $1.90 per share. The underwriters exercised in full their 30‑day option to buy up to 1,973,700 additional shares on the same terms. All shares are being sold by the company.
Including the option shares, net proceeds to Inovio are expected to be approximately $26.5 million after underwriting discounts and estimated expenses. The closing is expected on or about November 12, 2025, subject to customary conditions. The transaction is being conducted under an effective Form S‑3 shelf, supplemented by a prospectus filed pursuant to Rule 424(b).
Inovio Pharmaceuticals (INO) launched a primary offering of 13,158,000 shares of common stock via a prospectus supplement. The public offering price is $1.90 per share, implying gross proceeds of $25,000,200 and net proceeds of $23,500,188 after underwriting discounts and before expenses. The company granted underwriters a 30‑day option to purchase up to 1,973,700 additional shares at the public price, less discounts.
Inovio estimates approximately $23 million in net proceeds (or approximately $26.5 million if the option is exercised in full). The company plans to use the funds primarily to prepare for a potential commercial launch of INO‑3107, if approved, to advance its clinical pipeline, and for general corporate purposes. Shares outstanding were 53,571,675 as of September 30, 2025; the company states shares outstanding would be 66,729,675 immediately after this offering (or 68,703,375 if the option is fully exercised). Inovio expects that cash and this offering’s net proceeds will fund operations into the third quarter 2026.
Piper Sandler is the sole bookrunner. The Nasdaq Capital Market listing remains “INO,” and the last reported sale price on November 10, 2025 was $2.15 per share.
Inovio Pharmaceuticals launched a primary offering of common stock via a preliminary prospectus supplement under its effective shelf registration. Piper Sandler is bookrunning the deal, and the company granted the underwriters a 30‑day option to purchase additional shares at the public offering price, less discounts and commissions.
Inovio plans to use the proceeds primarily to prepare for a potential commercial launch of INO‑3107, if approved, to advance its clinical pipeline, and for general corporate purposes. The company reported that it completed submission of a Biologics License Application for INO‑3107 under the FDA’s accelerated approval program and requested priority review, targeting file acceptance by the end of 2025. Inovio’s common stock trades on Nasdaq as “INO,” and it is classified as a “smaller reporting company.”
Inovio Pharmaceuticals launched a primary offering of common stock via a preliminary prospectus supplement under its effective shelf registration. Piper Sandler is bookrunning the deal, and the company granted the underwriters a 30‑day option to purchase additional shares at the public offering price, less discounts and commissions.
Inovio plans to use the proceeds primarily to prepare for a potential commercial launch of INO‑3107, if approved, to advance its clinical pipeline, and for general corporate purposes. The company reported that it completed submission of a Biologics License Application for INO‑3107 under the FDA’s accelerated approval program and requested priority review, targeting file acceptance by the end of 2025. Inovio’s common stock trades on Nasdaq as “INO,” and it is classified as a “smaller reporting company.”
Inovio Pharmaceuticals (INO) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1.
Per Item 2.02 and General Instruction B.2, this information is being furnished and is not deemed filed under the Exchange Act. The report is dated November 10, 2025 and was signed by CFO Peter Kies.
Inovio Pharmaceuticals (INO) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1.
Per Item 2.02 and General Instruction B.2, this information is being furnished and is not deemed filed under the Exchange Act. The report is dated November 10, 2025 and was signed by CFO Peter Kies.
Inovio Pharmaceuticals (INO) reported Q3 2025 results with a net loss of $45.5 million (basic/diluted EPS $(0.87)) versus a loss of $25.2 million a year ago. Operating expenses declined year over year as research and development was $13.3 million (vs. $18.7 million) and general and administrative was $7.9 million (vs. $8.6 million). A $22.5 million increase in the fair value of warrant liabilities drove a sizeable other expense.
Cash and cash equivalents were $36.6 million and short-term investments were $14.2 million, totaling $50.8 million at September 30, 2025. Stockholders’ equity was $(7.7) million, down from $68.5 million at year-end 2024, reflecting cumulative losses and warrant liability remeasurement. Management states available liquidity is expected to support planned operations into the second quarter of 2026, and there is substantial doubt about the ability to continue as a going concern beyond the first quarter of 2026. The company closed a July 2025 equity-and-warrants financing with net proceeds of $22.4 million.
Inovio Pharmaceuticals (INO) reported Q3 2025 results with a net loss of $45.5 million (basic/diluted EPS $(0.87)) versus a loss of $25.2 million a year ago. Operating expenses declined year over year as research and development was $13.3 million (vs. $18.7 million) and general and administrative was $7.9 million (vs. $8.6 million). A $22.5 million increase in the fair value of warrant liabilities drove a sizeable other expense.
Cash and cash equivalents were $36.6 million and short-term investments were $14.2 million, totaling $50.8 million at September 30, 2025. Stockholders’ equity was $(7.7) million, down from $68.5 million at year-end 2024, reflecting cumulative losses and warrant liability remeasurement. Management states available liquidity is expected to support planned operations into the second quarter of 2026, and there is substantial doubt about the ability to continue as a going concern beyond the first quarter of 2026. The company closed a July 2025 equity-and-warrants financing with net proceeds of $22.4 million.
Inovio Pharmaceuticals, Inc. filed a current report to share that it issued a press release with its financial results for the quarter ended June 30, 2025. The press release, dated August 12, 2025, is attached as Exhibit 99.1 and incorporated by reference.
The company is using this report under Item 2.02, which covers results of operations and financial condition. The information in Item 2.02 and Exhibit 99.1 is being furnished, rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA medicines and CELLECTRA delivery devices, with lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP). In a completed Phase 1/2 trial of INO-3107, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following treatment versus the year prior.
For the quarter and six months ended June 30, 2025, the company reported net losses of $23.5 million and $43.2 million, respectively, with net loss per share of $0.61 for the quarter and $1.12 year-to-date. Cash and cash equivalents were $24.35 million and short-term investments were $23.20 million (combined $47.5 million). Working capital was $21.0 million, total assets $68.24 million, total stockholders' equity $28.53 million, and accumulated deficit $1.773 billion.
The company disclosed substantial doubt about its ability to continue as a going concern beyond Q2 2026, but closed a July 7, 2025 underwritten public offering that generated $22.5 million of net proceeds. Management resolved a prior manufacturing issue for a CELLECTRA disposable component and completed Design Verification testing.